Dr Lal Pathlabs Ltd News
Dr Lal Q3FY25 results: PAT jumps 19% to Rs 98 crore as volumes grow
As for Suburban Diagnostics, an arm of Dr Lal Pathlabs, revenue growth was 9.2 per cent in Q3
 "Dr Lal Q3FY25 results: PAT jumps 19% to Rs 98 crore as volumes grow")
Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore
The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore
 "Dr Lal Path Labs Q3FY25 results: Net profit jumps 19% to Rs 96.7 crore")
Nifty options hint max pain at 23,450; Adani Energy, UBL see short-covering
Meanwhile, NSE F&O data shows that FIIs were net sellers in Nifty futures for the sixth straight trading session on Tuesday, with net sales of 70,318 contracts in this period.
 "Nifty options hint max pain at 23,450; Adani Energy, UBL see short-covering")
HMPV scare: Vijaya, Dr Lal Path, healthcare stocks in focus; Time to buy?
Apollo Hospitals, Vijaya Diagnostic and Narayana Hrudayalaya have given a fresh breakout on the daily scale. Charts show that these 5 healthcare related shares can rally up to 11 per cent.
 "HMPV scare: Vijaya, Dr Lal Path, healthcare stocks in focus; Time to buy?")
F&O Market: Union Bank, Dabur see short build-up as Nifty tumbles 300pts
Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.
 "F&O Market: Union Bank, Dabur see short build-up as Nifty tumbles 300pts")
Dr Lal PathLabs up 4% on strong September qtr results; more details here
The uptick in Dr Lal PathLabs's share price came on the back of a healthy September quarter of financial year 2025 (Q2FY25) earnings
 "Dr Lal PathLabs up 4% on strong September qtr results; more details here")
Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%
The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India
 "Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%")
Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr
The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row
 "Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr")
RBI Policy: Will Bank Nifty fall to 50K or hit 52K today? Key levels here
Derivatives market update Oct 09: NSE F&O data shows that retail investors' are most bullish since the Lok Sabha poll outcome in June; their long-short ratio in index futures rose to 1.44.
 "RBI Policy: Will Bank Nifty fall to 50K or hit 52K today? Key levels here")
F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty
Derivatives market update: 12 stocks including Balrampur Chini, GNFC, India Cement, LIC Housing and National are in F&O ban on Thursday; 2 stocks see buildup up short positions; details here
 "F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty")
